Which country is suitable for overseas PGT - Comparative analysis of USA, Thailand, Russia, Georgia

Opening: Real consultation scenario

Consultation scenario ｜ A 39-year-old woman, AMH 1.2 ng/mL, unilateral hydrosalpinx, carrier of a balanced chromosomal translocation. After two failed IVF cycles domestically with no transferable embryos, she came with a thick stack of reports and asked: "I want to do PGT. The USA, Thailand, Russia, Georgia — which one should I choose?"

Module E: Differences between countries

Core differences in PGT across countries

The technical threshold, legal framework, and cost structure of PGT vary significantly between countries. Choosing a country essentially involves balancing medical quality, legal permissibility, accessibility, and budget. Below, we break down the characteristics of the four main destinations from a real practitioner's perspective.

Country	PGT technical coverage	Legal environment	Cost per cycle (CNY)	Main advantages	Main limitations
USA	Full coverage: PGT-A / PGT-M / PGT-SR	Varies by state; high support in California/New York	210,000 – 360,000 (30,000 – 50,000 USD)	Most advanced technology, highest lab standards, comprehensive genetic counseling system	High cost, visa required, long flight time
Thailand	Primarily PGT-A; PGT-M partially restricted	Sex selection prohibited; egg/sperm donation allowed	80,000 – 120,000	Outstanding cost-effectiveness, close proximity, mature medical tourism infrastructure	Sex selection restricted; some genetic disease testing requires overseas referral
Russia	PGT-A / PGT-M	Sex selection allowed; egg/sperm donation allowed	100,000 – 150,000	Lenient laws, mature technology, embryos can be cryopreserved	International situation affects travel; unstable flights
Georgia	Primarily PGT-A	Sex selection allowed; legally friendly	60,000 – 100,000	Low cost, lenient laws, simple visa process	Limited medical resources; weak capacity for complex genetic disease testing

Module A: Direct answer to the question

Which country is actually suitable?

From a medical decision-making logic, the answer depends on three core variables: complexity of the genetic issue, budget range, and acceptance of legal restrictions.

• Complex single-gene disorders (e.g., thalassemia, DMD, cystic fibrosis) or chromosomal structural abnormalities (e.g., balanced translocation, inversion): The USA is the first choice because PGT-M and PGT-SR have the most rigorous technical validation, and the genetic counseling system is comprehensive, allowing for personalized probe design for specific mutations.
• Aneuploidy screening (PGT-A) or recurrent miscarriage, advanced age: Thailand offers the best cost-effectiveness, mature technology, short flight time, and complete medical support. The PGT-A live detection rate in several mainstream Thai labs is now very close to that in Europe and the USA.
• Need for sex selection or egg/sperm donation: Russia and Georgia explicitly allow it by law. Russia has a higher level of embryology labs, while Georgia has lower costs.
• Limited budget and simple needs (PGT-A only): Georgia can be a backup option, but you must confirm whether the lab holds international certifications (e.g., CAP, ISO15189).

Module C: Doctor's perspective

From a reproductive doctor's perspective: the medical logic of choosing a country

In clinical decision-making, doctors prioritize evaluating the patient's embryo biopsy risk and accuracy of genetic testing, rather than cost or distance.

• Embryo biopsy technique: The USA mainly uses laser-assisted trophectoderm biopsy, with a post-biopsy embryo freeze-thaw survival rate above 95%. Some less experienced labs may use mechanical methods, with a slightly higher damage rate. For patients with low ovarian reserve (AMH < 1.0) and few embryos, the precision of the biopsy technique directly determines the cycle outcome.
• Genetic testing platform: The USA commonly uses NGS (next-generation sequencing) + SNP array, which can simultaneously detect chromosomal copy number variations and uniparental disomy. Thailand and Russia mainly use NGS, but additional validation is needed for single-gene disorders. Some labs in Georgia still use aCGH (array comparative genomic hybridization), which has lower resolution than NGS.
• Genetic counseling capability: The USA requires genetic counselors to be involved in all PGT-M cases to ensure accurate probe design and complete linkage analysis. This is not yet fully普及 in other countries.

Therefore, from a medical safety perspective: Complex genetic issues → USA; routine chromosomal screening → Thailand or Russia; extremely low budget and no genetic history → Georgia may be considered.

Module G: Easiest details to overlook

Five details most easily overlooked

1. Lab certification ≠ hospital reputation: Many patients only look at the hospital brand, but the core of PGT is the embryology lab. Confirming whether the lab holds CAP (College of American Pathologists), CLIA (Clinical Laboratory Improvement Amendments), or ISO15189 certification is far more important than looking at photos on the hospital website.
2. Legal permission ≠ unrestricted practical operation: Thai law prohibits sex selection, but some institutions operate in a gray area through "embryo prioritization," posing compliance risks. Russian law allows sex selection, but when it comes to egg donation, the donor's anonymity is strictly protected, which may affect the offspring's right to know.
3. Embryo freezing and cross-border transport: If you plan to have the biopsy in country A and transfer in country B, you need to confirm the legal and logistical feasibility of embryo transport between the two countries. Currently, there are mature embryo transport routes between China-USA and China-Thailand, but the routes between China-Russia and China-Georgia are not well-established, and the transport process carries a risk of thawing.
4. Time difference affects medical communication: The time difference between the US West Coast and China is 15 hours. Medical coordination often relies on email or messages, and emergency response is slow. Thailand has only a 1-hour time difference, allowing real-time video communication. For patients who need frequent medication adjustments, the time difference is a practical obstacle.
5. Follow-up and transfer arrangements: If you need a second transfer after PGT in the USA, you must reapply for a visa. In Thailand or Georgia, visa-on-arrival or visa-free policies make follow-ups more convenient. For patients with chronic conditions (e.g., thyroid dysfunction, insulin resistance) requiring frequent medication adjustments, choosing a closer destination is safer.

Module H: Common pitfalls

Three most common traps

Module J: Timeline

Timelines and planning suggestions by country

From initial consultation to embryo transfer, the cycle length across different countries is not significantly different (about 2–3 months), but preparation time and visa processing time vary.

Stage	USA	Thailand	Russia	Georgia
Visa processing	B2 visa, 1–3 months waiting	Visa on arrival/tourist visa, 1–2 weeks	Electronic visa, 2–4 weeks	Visa-free/electronic visa, 1–2 weeks
Domestic tests and file setup	2–4 weeks (AMH, hormones, semen analysis, karyotype, infectious disease screening)
Ovarian stimulation + egg retrieval	12–15 days (stay required in target country)
Embryo culture + biopsy	5–7 days (completed in lab)
PGT testing period	2–4 weeks	2–3 weeks	3–4 weeks	3–5 weeks
Transfer (frozen embryo cycle)	Requires another visit, stay 5–7 days
Total planning time	4–6 months	2.5–4 months	3–5 months	2.5–4 months

Recommendation: Start preparation at least 3 months in advance. If AMH is low or age > 40, prioritize completing antral follicle count (AFC) and AMH testing before deciding on a destination. Some tests (e.g., karyotype, genetic counseling) require appointments, and waiting times at top-tier hospitals in China can be 1–3 weeks.

Module K: Cost factors

Cost structure and hidden expenses

The cost of PGT is composed of multiple independent components, and the charging models vary greatly between countries. Below, we break down the real cost structure based on "one cycle of stimulation + PGT-A + one transfer."

• Medical fees (50%–70% of total): Includes stimulation medications, egg retrieval surgery, embryo culture, embryo biopsy, PGT testing, freezing, and transfer. The USA has the highest medical costs, with PGT testing fees around 800–1200 USD per embryo; in Thailand, PGT testing fees are about 3000–6000 THB per embryo; Georgia charges a package price per number of embryos.
• Medication cost differences: The USA uses imported stimulation drugs (Gonal-F, Menopur), costing about 3000–5000 USD per cycle. Thailand offers a combination of domestic and imported drugs, costing about 15,000–25,000 CNY. Russia and Georgia mainly use European drugs, with moderate costs.
• Living and travel costs: 14 days of accommodation + flights in the USA: about 30,000–50,000 CNY; Thailand: about 15,000–25,000 CNY; Russia and Georgia: about 10,000–20,000 CNY.
• Hidden costs: Genetic counseling fees (USA: about 500–1500 USD), additional embryo freezing fees (annual charge), embryo transport fees (about 2000–5000 USD), legal fees (if donation or surrogacy agreements are needed).

Module O: Suitable populations

Country recommendations for different groups

Naturally integrated long-tail keywords and knowledge graph entities Module: Special situation handling

Special situations and coping strategies

• No embryos available for transfer after previous PGT: Analyze whether it is due to egg quality issues, high sperm DNA fragmentation, or lab technique problems. It is recommended to complete sperm DFI testing and oocyte morphology assessment before changing destinations. If it is a lab issue, consider transporting embryos from the USA to Thailand or Russia.
• Uterine factors (adenomyosis, adhesions, endometritis): Hysteroscopy and treatment should be completed locally before transfer. Some countries (e.g., Thailand) can perform uterine surgery and ovarian stimulation simultaneously to reduce the number of cycles.
• HIV/Hepatitis B and other infectious diseases: The USA and Thailand have higher acceptance of infectious disease carriers, with specialized embryo washing and testing protocols. Russian and Georgian laws do not explicitly prohibit it, but the medical team must be informed in advance.
• Need for egg donation: Russia and Georgia have richer egg bank resources with shorter waiting times; the USA has the strictest background checks for egg donors but higher costs (about 20,000–40,000 USD). Egg donation laws in Thailand are more complex; Russia is recommended as a priority.

Ending: Doctor's advice Risk reminder (naturally integrated)

Risk reminder: PGT cannot 100% guarantee a normal embryo or ensure a live birth after transfer. All medical procedures carry risks of anesthesia, infection, and ovarian hyperstimulation syndrome (OHSS). Before choosing an overseas medical institution, it is recommended to verify its practice license and certification information through official channels. This content is for reference only and does not constitute medical advice.